[L02BA01, tamoxifen, The excretion of Silodosin can be decreased when combined with Tamoxifen.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Silodosin.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Silodosin.]
[N05AE05, lurasidone, Silodosin may increase the hypotensive activities of Lurasidone.]
[N05AB08, thioproperazine, Thioproperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N05AC02, thioridazine, Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[S01ED01, timolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Timolol is combined with Silodosin.]
[M02AX02, tolazoline, The risk or severity of orthostatic hypotension and dizziness can be increased when Tolazoline is combined with Silodosin.]
[N06AX05, trazodone, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C03AA06, trichlormethiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Trichlormethiazide is combined with Silodosin.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[A03AA05, trimebutine, The risk or severity of hypotension can be increased when Silodosin is combined with Trimebutine.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Silodosin is combined with Trimethadione.]
[C02BA01, trimethaphan, The risk or severity of orthostatic hypotension and dizziness can be increased when Trimethaphan is combined with Silodosin.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[J01FA08, troleandomycin, The metabolism of Silodosin can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of orthostatic hypotension and dizziness can be increased when Azilsartan medoxomil is combined with Silodosin.]
[L01EX04, vandetanib, The excretion of Silodosin can be decreased when combined with Vandetanib.]
[A10BH05, linagliptin, The excretion of Silodosin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Silodosin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The excretion of Silodosin can be decreased when combined with Telaprevir.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Silodosin.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Silodosin.]
[B01AC24, ticagrelor, The excretion of Silodosin can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The excretion of Silodosin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Silodosin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Silodosin.]
[C04AX07, vincamine, The risk or severity of orthostatic hypotension and dizziness can be increased when Vincamine is combined with Silodosin.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Silodosin.]
[S01AA13, fusidic acid, The metabolism of Silodosin can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, The risk or severity of orthostatic hypotension and dizziness can be increased when Xipamide is combined with Silodosin.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[J05AE02, indinavir, The metabolism of Silodosin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The excretion of Silodosin can be decreased when combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Silodosin.]
[L01ED01, crizotinib, The excretion of Silodosin can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Silodosin can be decreased when combined with Ziprasidone.]
[C07AB03, atenolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Atenolol is combined with Silodosin.]
[J02AC03, voriconazole, The metabolism of Silodosin can be decreased when combined with Voriconazole.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Silodosin.]
[R07AX02, ivacaftor, The excretion of Silodosin can be decreased when combined with Ivacaftor.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Silodosin.]
[G04BE10, avanafil, Silodosin may increase the hypotensive activities of Avanafil.]
[G04BD12, mirabegron, The excretion of Silodosin can be decreased when combined with Mirabegron.]
[L01XG02, carfilzomib, The excretion of Silodosin can be decreased when combined with Carfilzomib.]
[V03AX03, cobicistat, The excretion of Silodosin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Silodosin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Silodosin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Silodosin.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Silodosin.]
[L01EX05, regorafenib, The excretion of Silodosin can be decreased when combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Silodosin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Silodosin.]
[C08CA13, lercanidipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Lercanidipine is combined with Silodosin.]
[G04BE03, sildenafil, The excretion of Silodosin can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The excretion of Silodosin can be decreased when combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Silodosin.]
[C10AX12, lomitapide, The excretion of Silodosin can be decreased when combined with Lomitapide.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Silodosin is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Bendroflumethiazide is combined with Silodosin.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Silodosin.]
[A10BK02, canagliflozin, The excretion of Silodosin can be decreased when combined with Canagliflozin.]
[A06AX06, tegaserod, The serum concentration of Silodosin can be increased when it is combined with Tegaserod.]
[L04AA18, everolimus, The excretion of Silodosin can be decreased when combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.]
[L01EB03, afatinib, The excretion of Silodosin can be decreased when combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Silodosin.]
[C08EA02, bepridil, The risk or severity of orthostatic hypotension and dizziness can be increased when Bepridil is combined with Silodosin.]
[C02KX05, riociguat, The risk or severity of orthostatic hypotension and dizziness can be increased when Riociguat is combined with Silodosin.]
[C02KX04, macitentan, The risk or severity of orthostatic hypotension and dizziness can be increased when Macitentan is combined with Silodosin.]
[D01AC18, luliconazole, The metabolism of Silodosin can be decreased when combined with Luliconazole.]
[J05AP05, simeprevir, The excretion of Silodosin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Silodosin.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Silodosin.]
[C07AB04, acebutolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Acebutolol is combined with Silodosin.]
[A16AA07, metreleptin, The metabolism of Silodosin can be increased when combined with Metreleptin.]
[S01ED02, betaxolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Betaxolol is combined with Silodosin.]
[C02CC01, bethanidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Bethanidine is combined with Silodosin.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Silodosin.]
[B01AC26, vorapaxar, The excretion of Silodosin can be decreased when combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Silodosin can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Silodosin.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Silodosin.]
[N05CM19, suvorexant, The excretion of Silodosin can be decreased when combined with Suvorexant.]
[A16AX10, eliglustat, The excretion of Silodosin can be decreased when combined with Eliglustat.]
[N05AA04, acepromazine, Acepromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Silodosin.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Silodosin.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Silodosin.]
[L01EF01, palbociclib, The excretion of Silodosin can be decreased when combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Silodosin.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Silodosin.]
[J05AP07, daclatasvir, The excretion of Silodosin can be decreased when combined with Daclatasvir.]
[J05AP06, asunaprevir, The excretion of Silodosin can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[A04AD14, rolapitant, The excretion of Silodosin can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The excretion of Silodosin can be decreased when combined with Flibanserin.]
[J02AC05, isavuconazole, The excretion of Silodosin can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Silodosin.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Silodosin.]
[B01AC27, selexipag, The risk or severity of orthostatic hypotension and dizziness can be increased when Selexipag is combined with Silodosin.]
[G04CA01, alfuzosin, Silodosin may increase the hypotensive activities of Alfuzosin.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Silodosin.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Silodosin.]
[L01XX52, venetoclax, The excretion of Silodosin can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C08CA01, amlodipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Amlodipine is combined with Silodosin.]
[C07AA19, bupranolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Bupranolol is combined with Silodosin.]
[L01XX27, arsenic trioxide, The excretion of Silodosin can be decreased when combined with Arsenic trioxide.]
[L01EF02, ribociclib, The metabolism of Silodosin can be decreased when combined with Ribociclib.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Silodosin.]
[C09AA07, benazepril, The risk or severity of orthostatic hypotension and dizziness can be increased when Benazepril is combined with Silodosin.]
[J05AE09, tipranavir, The excretion of Silodosin can be decreased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Silodosin can be decreased when combined with Midostaurin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Silodosin.]
[L01XX59, enasidenib, The excretion of Silodosin can be decreased when combined with Enasidenib.]
[L01EH02, neratinib, The excretion of Silodosin can be decreased when combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Silodosin.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Silodosin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Silodosin.]
[C07AB07, bisoprolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Bisoprolol is combined with Silodosin.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Silodosin.]
[J05AG03, efavirenz, The metabolism of Silodosin can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Silodosin.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Silodosin.]
[C09AA01, captopril, The risk or severity of orthostatic hypotension and dizziness can be increased when Captopril is combined with Silodosin.]
[L02BB05, apalutamide, The serum concentration of Silodosin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Silodosin can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The excretion of Silodosin can be decreased when combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Silodosin.]
[N03AX24, cannabidiol, The metabolism of Silodosin can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Silodosin.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Silodosin.]
[C07AB08, celiprolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Celiprolol is combined with Silodosin.]
[H01CC03, elagolix, The excretion of Silodosin can be decreased when combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Silodosin can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The excretion of Silodosin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Silodosin.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Silodosin.]
[L01EB07, dacomitinib, The excretion of Silodosin can be decreased when combined with Dacomitinib.]
[J01AA14, sarecycline, The excretion of Silodosin can be decreased when combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Silodosin.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Silodosin.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Silodosin.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Silodosin.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Silodosin.]
[L01XJ03, glasdegib, The excretion of Silodosin can be decreased when combined with Glasdegib.]
[C09AA08, cilazapril, The risk or severity of orthostatic hypotension and dizziness can be increased when Cilazapril is combined with Silodosin.]
[J01FA09, clarithromycin, The excretion of Silodosin can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The excretion of Silodosin can be decreased when combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Silodosin can be increased when it is combined with Clobazam.]
[C09CA06, candesartan, The risk or severity of orthostatic hypotension and dizziness can be increased when Candesartan is combined with Silodosin.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Silodosin.]
[C03BX03, cicletanine, The risk or severity of orthostatic hypotension and dizziness can be increased when Cicletanine is combined with Silodosin.]
[L01EJ02, fedratinib, The excretion of Silodosin can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The excretion of Silodosin can be decreased when combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Silodosin can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Lefamulin can be increased when it is combined with Silodosin.]
[N04CX01, istradefylline, The excretion of Silodosin can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Cyclothiazide is combined with Silodosin.]
[J01XX09, daptomycin, The serum concentration of Silodosin can be increased when it is combined with Daptomycin.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Silodosin.]
[N02CC08, lasmiditan, The excretion of Silodosin can be decreased when combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Silodosin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Silodosin.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Silodosin.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Silodosin.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Silodosin.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Silodosin.]
[J05AE05, amprenavir, The metabolism of Silodosin can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Silodosin.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Silodosin is combined with Clevidipine.]
[C01BD07, dronedarone, The excretion of Silodosin can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Methoserpidine is combined with Silodosin.]
[L01EH03, tucatinib, The excretion of Silodosin can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Silodosin can be decreased when combined with Capmatinib.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Silodosin.]
[L01EX19, ripretinib, The excretion of Silodosin can be decreased when combined with Ripretinib.]
[C08CA17, levamlodipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Levamlodipine is combined with Silodosin.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Silodosin.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Silodosin.]
[L04AC19, satralizumab, The serum concentration of Silodosin can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The excretion of Silodosin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Chlorothiazide is combined with Silodosin.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C03BA04, chlorthalidone, The risk or severity of orthostatic hypotension and dizziness can be increased when Chlorthalidone is combined with Silodosin.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Silodosin is combined with Vinpocetine.]
[B06AC06, berotralstat, The metabolism of Silodosin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The excretion of Silodosin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Silodosin.]
[L04AD03, voclosporin, The excretion of Silodosin can be decreased when combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Silodosin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The excretion of Silodosin can be decreased when combined with Tepotinib.]
[L01EX25, umbralisib, The excretion of Silodosin can be decreased when combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Silodosin.]
[C01CA19, fenoldopam, The risk or severity of orthostatic hypotension and dizziness can be increased when Fenoldopam is combined with Silodosin.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Silodosin.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Silodosin.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Silodosin.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Silodosin is combined with Cinnarizine.]
[L01XX73, sotorasib, The excretion of Silodosin can be decreased when combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Silodosin can be decreased when combined with Ciprofloxacin.]
[L04AA48, belumosudil, The excretion of Silodosin can be decreased when combined with Belumosudil.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Silodosin.]
[M01AG01, mefenamic acid, The metabolism of Silodosin can be decreased when combined with Mefenamic acid.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Silodosin.]
[N06AX25, St. John's wort extract, The metabolism of Silodosin can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The excretion of Silodosin can be decreased when combined with Asciminib.]
[J05AX10, maribavir, The excretion of Silodosin can be decreased when combined with Maribavir.]
[D11AH08, abrocitinib, The excretion of Silodosin can be decreased when combined with Abrocitinib.]
[J04BA01, clofazimine, The excretion of Silodosin can be decreased when combined with Clofazimine.]
[B06AX04, mitapivat, The excretion of Silodosin can be decreased when combined with Mitapivat.]
[L01EJ03, pacritinib, The excretion of Silodosin can be decreased when combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Silodosin can be increased when it is combined with Clomifene.]
[S01EA04, clonidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Clonidine is combined with Silodosin.]
[C01EB24, mavacamten, The serum concentration of Silodosin can be decreased when it is combined with Mavacamten.]
[N05AH02, clozapine, The metabolism of Silodosin can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Silodosin.]
[A10BK06, sotagliflozin, The excretion of Silodosin can be decreased when combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Silodosin can be increased when combined with Somatrogon.]
[C02KB01, metyrosine, The risk or severity of orthostatic hypotension and dizziness can be increased when Metyrosine is combined with Silodosin.]
[M04AC01, colchicine, The serum concentration of Silodosin can be increased when it is combined with Colchicine.]
[J01FA15, telithromycin, The metabolism of Silodosin can be decreased when combined with Telithromycin.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Silodosin.]
[J02AC02, itraconazole, The excretion of Silodosin can be decreased when combined with Itraconazole.]
[J02AC04, posaconazole, The metabolism of Silodosin can be decreased when combined with Posaconazole.]
[S01EE03, bimatoprost, The risk or severity of orthostatic hypotension and dizziness can be increased when Bimatoprost is combined with Silodosin.]
[C08CA09, lacidipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Lacidipine is combined with Silodosin.]
[N07BC04, lofexidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Lofexidine is combined with Silodosin.]
[C09AA03, lisinopril, The risk or severity of orthostatic hypotension and dizziness can be increased when Lisinopril is combined with Silodosin.]
[C08CA11, manidipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Manidipine is combined with Silodosin.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Silodosin.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Silodosin is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Methoxyphenamine.]
[C03DA04, eplerenone, The risk or severity of orthostatic hypotension and dizziness can be increased when Eplerenone is combined with Silodosin.]
[C03AA07, cyclopenthiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Cyclopenthiazide is combined with Silodosin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Silodosin can be increased when it is combined with Tenofovir disoproxil.]
[S01XA18, cyclosporine, The excretion of Silodosin can be decreased when combined with Cyclosporine.]
[C09AA13, moexipril, The risk or severity of orthostatic hypotension and dizziness can be increased when Moexipril is combined with Silodosin.]
[C03XA02, conivaptan, The excretion of Silodosin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Moxonidine is combined with Silodosin.]
[G04BE09, vardenafil, The excretion of Silodosin can be decreased when combined with Vardenafil.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Silodosin.]
[G03XA01, danazol, The metabolism of Silodosin can be decreased when combined with Danazol.]
[C02CC04, debrisoquin, The risk or severity of orthostatic hypotension and dizziness can be increased when Debrisoquine is combined with Silodosin.]
[C07AB12, nebivolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Nebivolol is combined with Silodosin.]
[N06AX06, nefazodone, The metabolism of Silodosin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, The risk or severity of orthostatic hypotension and dizziness can be increased when Nicorandil is combined with Silodosin.]
[C01CA23, theodrenaline, Silodosin may decrease the hypertensive activities of Theodrenaline.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Silodosin.]
[C09XA02, aliskiren, The risk or severity of orthostatic hypotension and dizziness can be increased when Aliskiren is combined with Silodosin.]
[S03BA01, dexamethasone, The metabolism of Silodosin can be increased when combined with Dexamethasone.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Amphetamine.]
[V03AH01, diazoxide, The risk or severity of orthostatic hypotension and dizziness can be increased when Diazoxide is combined with Silodosin.]
[C02DG01, pinacidil, The risk or severity of orthostatic hypotension and dizziness can be increased when Pinacidil is combined with Silodosin.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Silodosin is combined with Pinaverium.]
[L01DC04, ixabepilone, The excretion of Silodosin can be decreased when combined with Ixabepilone.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Silodosin.]
[A08AA03, diethylpropion, The therapeutic efficacy of Silodosin can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The metabolism of Silodosin can be decreased when combined with Isradipine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Silodosin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Silodosin.]
[C02DB01, dihydralazine, The risk or severity of orthostatic hypotension and dizziness can be increased when Dihydralazine is combined with Silodosin.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[J05AE08, atazanavir, The metabolism of Silodosin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of orthostatic hypotension and dizziness can be increased when Treprostinil is combined with Silodosin.]
[C08DB01, diltiazem, The metabolism of Silodosin can be decreased when combined with Diltiazem.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Silodosin.]
[C05CA03, diosmin, The excretion of Silodosin can be decreased when combined with Diosmin.]
[C09AA06, quinapril, The risk or severity of orthostatic hypotension and dizziness can be increased when Quinapril is combined with Silodosin.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Silodosin.]
[C09AA05, ramipril, The risk or severity of orthostatic hypotension and dizziness can be increased when Ramipril is combined with Silodosin.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Silodosin.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Silodosin.]
[S02AA12, rifamycin SV, The excretion of Silodosin can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Silodosin can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[A04AD12, aprepitant, The metabolism of Silodosin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Silodosin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Silodosin.]
[G04BE08, tadalafil, The risk or severity of orthostatic hypotension and dizziness can be increased when Tadalafil is combined with Silodosin.]
[C02KX02, ambrisentan, The risk or severity of orthostatic hypotension and dizziness can be increased when Ambrisentan is combined with Silodosin.]
[C01EB18, ranolazine, The excretion of Silodosin can be decreased when combined with Ranolazine.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Silodosin.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Silodosin.]
[N06AA12, doxepin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N05AD08, droperidol, Droperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C10AA01, simvastatin, The excretion of Silodosin can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, The risk or severity of orthostatic hypotension and dizziness can be increased when Spirapril is combined with Silodosin.]
[G01AF05, econazole, The metabolism of Silodosin can be decreased when combined with Econazole.]
[C07AB13, talinolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Talinolol is combined with Silodosin.]
[G04CA03, terazosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Terazosin is combined with Silodosin.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Silodosin is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Silodosin.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Silodosin.]
[C09AA02, enalapril, The risk or severity of orthostatic hypotension and dizziness can be increased when Enalapril is combined with Silodosin.]
[G01AF08, tioconazole, The metabolism of Silodosin can be decreased when combined with Tioconazole.]
[L02BA02, toremifene, The excretion of Silodosin can be decreased when combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of orthostatic hypotension and dizziness can be increased when Torasemide is combined with Silodosin.]
[C09AA10, trandolapril, The risk or severity of orthostatic hypotension and dizziness can be increased when Trandolapril is combined with Silodosin.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Silodosin.]
[C02CA06, urapidil, The risk or severity of orthostatic hypotension and dizziness can be increased when Urapidil is combined with Silodosin.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Silodosin.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Silodosin.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Silodosin.]
[C08CA12, mepirodipine, The metabolism of Silodosin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Silodosin.]
[C09AA15, zofenopril, The risk or severity of orthostatic hypotension and dizziness can be increased when Zofenopril is combined with Silodosin.]
[N03AX15, zonisamide, The excretion of Silodosin can be decreased when combined with Zonisamide.]
[C02AC02, guanfacine, The risk or severity of orthostatic hypotension and dizziness can be increased when Guanfacine is combined with Silodosin.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Silodosin.]
[N02CA02, ergotamine, The metabolism of Silodosin can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The excretion of Silodosin can be decreased when combined with Erythromycin.]
[C01CA15, gepefrine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Gepefrine.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Silodosin is combined with Ethosuximide.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Silodosin.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Silodosin.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Silodosin.]
[L04AD02, tacrolimus, The excretion of Silodosin can be decreased when combined with Tacrolimus.]
[R06AX12, terfenadine, The metabolism of Silodosin can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Silodosin can be decreased when combined with Fluvoxamine.]
[C10AA03, pravastatin, The serum concentration of Silodosin can be increased when it is combined with Pravastatin.]
[A05AA01, chenodeoxycholic acid, The metabolism of Silodosin can be decreased when combined with Chenodeoxycholic acid.]
[C08CA02, felodipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Felodipine is combined with Silodosin.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Silodosin is combined with Fendiline.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Silodosin.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Silodosin.]
[J02AC01, fluconazole, The excretion of Silodosin can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Silodosin is combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Silodosin can be decreased when combined with Flunitrazepam.]
[N05AF01, flupenthixol, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N05AG01, fluspirilene, The risk or severity of hypotension can be increased when Silodosin is combined with Fluspirilene.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Silodosin.]
[J05AE10, darunavir, The metabolism of Silodosin can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of orthostatic hypotension and dizziness can be increased when Furosemide is combined with Silodosin.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Silodosin is combined with Gallopamil.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Silodosin.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Silodosin.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Silodosin is combined with Methsuximide.]
[L01EH01, lapatinib, The excretion of Silodosin can be decreased when combined with Lapatinib.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Silodosin.]
[C05AE01, nitroglycerin, The risk or severity of orthostatic hypotension and dizziness can be increased when Nitroglycerin is combined with Silodosin.]
[C02CA04, doxazosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Doxazosin is combined with Silodosin.]
[L01EX02, sorafenib, The excretion of Silodosin can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Esmolol is combined with Silodosin.]
[C09AA09, fosinopril, The risk or severity of orthostatic hypotension and dizziness can be increased when Fosinopril is combined with Silodosin.]
[S01EX01, guanethidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Guanethidine is combined with Silodosin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Silodosin.]
[N05AH04, quetiapine, Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C09CA01, losartan, The risk or severity of orthostatic hypotension and dizziness can be increased when Losartan is combined with Silodosin.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Silodosin.]
[C08CA10, nilvadipine, The metabolism of Silodosin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Silodosin is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of orthostatic hypotension and dizziness can be increased when Perindopril is combined with Silodosin.]
[C02DB02, hydralazine, The risk or severity of orthostatic hypotension and dizziness can be increased when Hydralazine is combined with Silodosin.]
[C03AA03, hydrochlorothiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Hydrochlorothiazide is combined with Silodosin.]
[C03AA02, hydroflumethiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Hydroflumethiazide is combined with Silodosin.]
[G04BD06, propiverine, Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[C02AC06, rilmenidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Rilmenidine is combined with Silodosin.]
[N06AA02, imipramine, Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Silodosin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Silodosin.]
[C03BA11, indapamide, The risk or severity of orthostatic hypotension and dizziness can be increased when Indapamide is combined with Silodosin.]
[S01BC01, indomethacin, The metabolism of Silodosin can be decreased when combined with Indomethacin.]
[C02CA02, indoramin, The risk or severity of orthostatic hypotension and dizziness can be increased when Indoramin is combined with Silodosin.]
[N06AX17, milnacipran, The metabolism of Silodosin can be decreased when combined with Milnacipran.]
[A10BH01, sitagliptin, The serum concentration of Silodosin can be increased when it is combined with Sitagliptin.]
[C07AA01, alprenolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Alprenolol is combined with Silodosin.]
[S01EC03, dorzolamide, The risk or severity of orthostatic hypotension and dizziness can be increased when Dorzolamide is combined with Silodosin.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Silodosin.]
[C09AA16, imidapril, The risk or severity of orthostatic hypotension and dizziness can be increased when Imidapril is combined with Silodosin.]
[J04AC01, isoniazid, The metabolism of Silodosin can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Silodosin.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Silodosin.]
[C02KD01, ketanserin, The risk or severity of orthostatic hypotension and dizziness can be increased when Ketanserin is combined with Silodosin.]
[J02AB02, ketoconazole, The excretion of Silodosin can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The excretion of Silodosin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Silodosin.]
[C07AG01, labetalol, The risk or severity of orthostatic hypotension and dizziness can be increased when Labetalol is combined with Silodosin.]
[C02AA05, deserpidine, The risk or severity of orthostatic hypotension and dizziness can be increased when Deserpidine is combined with Silodosin.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Silodosin is combined with Lidoflazine.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Silodosin is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Silodosin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The excretion of Silodosin can be decreased when combined with Loxapine.]
[L01EG01, temsirolimus, The excretion of Silodosin can be decreased when combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The risk or severity of hypotension can be increased when Silodosin is combined with Magnesium sulfate.]
[L01EA03, nilotinib, The excretion of Silodosin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Silodosin can be increased when it is combined with Mannitol.]
[C02BB01, mecamylamine, The risk or severity of orthostatic hypotension and dizziness can be increased when Mecamylamine is combined with Silodosin.]
[P01BC02, mefloquine, The excretion of Silodosin can be decreased when combined with Mefloquine.]
[C01CA11, mephentermine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Mephentermine.]
[N05AX13, paliperidone, The excretion of Silodosin can be decreased when combined with Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Silodosin.]
[N06BA03, methamphetamine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Metamfetamine.]
[H03BB02, methimazole, The metabolism of Silodosin can be decreased when combined with Methimazole.]
[N02BG08, ziconotide, The risk or severity of hypotension can be increased when Silodosin is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Silodosin.]
[C02AB01, methyldopa, The risk or severity of orthostatic hypotension and dizziness can be increased when Methyldopa is combined with Silodosin.]
[V04CG05, methylene blue, The excretion of Silodosin can be decreased when combined with Methylene blue.]
[C03BA08, metolazone, The risk or severity of orthostatic hypotension and dizziness can be increased when Metolazone is combined with Silodosin.]
[C07AB02, metoprolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Metoprolol is combined with Silodosin.]
[S02AA13, miconazole, The metabolism of Silodosin can be decreased when combined with Miconazole.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Silodosin.]
[G03XB01, mifepristone, The excretion of Silodosin can be decreased when combined with Mifepristone.]
[C09CA03, valsartan, The risk or severity of orthostatic hypotension and dizziness can be increased when Valsartan is combined with Silodosin.]
[D11AX01, minoxidil, The risk or severity of orthostatic hypotension and dizziness can be increased when Minoxidil is combined with Silodosin.]
[L01XX23, mitotane, The metabolism of Silodosin can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Lisdexamfetamine.]
[C01BD01, amiodarone, The excretion of Silodosin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N02AA01, morphine, The serum concentration of Silodosin can be increased when it is combined with Morphine.]
[B02BX05, eltrombopag, The metabolism of Silodosin can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N03AB05, fosphenytoin, The metabolism of Silodosin can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Nadolol is combined with Silodosin.]
[V03AB15, naloxone, The metabolism of Silodosin can be decreased when combined with Naloxone.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Silodosin.]
[N06BA01, amphetamine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Amphetamine.]
[N05AX14, iloperidone, Iloperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N06AX23, desvenlafaxine, The metabolism of Silodosin can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of orthostatic hypotension and dizziness can be increased when Telmisartan is combined with Silodosin.]
[C08CA04, nicardipine, The metabolism of Silodosin can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Silodosin is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Nimodipine is combined with Silodosin.]
[C08CA07, nisoldipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Nisoldipine is combined with Silodosin.]
[C08CA08, nitrendipine, The risk or severity of orthostatic hypotension and dizziness can be increased when Nitrendipine is combined with Silodosin.]
[C02DD01, nitroprusside, The risk or severity of orthostatic hypotension and dizziness can be increased when Nitroprusside is combined with Silodosin.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Silodosin.]
[C02KX01, bosentan, The risk or severity of orthostatic hypotension and dizziness can be increased when Bosentan is combined with Silodosin.]
[N06AA10, nortriptyline, Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[A16AX07, sapropterin, The excretion of Silodosin can be decreased when combined with Sapropterin.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Silodosin.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Silodosin.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C07AA02, oxprenolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Oxprenolol is combined with Silodosin.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Silodosin.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Silodosin.]
[N05AH05, asenapine, Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[C02KC01, pargyline, The risk or severity of orthostatic hypotension and dizziness can be increased when Pargyline is combined with Silodosin.]
[C07AA23, penbutolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Penbutolol is combined with Silodosin.]
[N05AG03, penfluridol, The risk or severity of hypotension can be increased when Silodosin is combined with Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Silodosin can be increased when combined with Pentobarbital.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Silodosin.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Silodosin is combined with Perhexiline.]
[N03AA02, phenobarbital, The metabolism of Silodosin can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The risk or severity of orthostatic hypotension and dizziness can be increased when Phenoxybenzamine is combined with Silodosin.]
[A08AA01, phentermine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, The risk or severity of orthostatic hypotension and dizziness can be increased when Phentolamine is combined with Silodosin.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Silodosin.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Silodosin.]
[N03AB02, phenytoin, The metabolism of Silodosin can be increased when combined with Phenytoin.]
[C08CX01, mibefradil, The excretion of Silodosin can be decreased when combined with Mibefradil.]
[C07AA03, pindolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Pindolol is combined with Silodosin.]
[J05AE01, saquinavir, The excretion of Silodosin can be decreased when combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of orthostatic hypotension and dizziness can be increased when Eprosartan is combined with Silodosin.]
[N02CX01, pizotyline, Pizotifen may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[J05AG02, delavirdine, The metabolism of Silodosin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of orthostatic hypotension and dizziness can be increased when Irbesartan is combined with Silodosin.]
[C03AA05, polythiazide, The risk or severity of orthostatic hypotension and dizziness can be increased when Polythiazide is combined with Silodosin.]
[J05AE03, ritonavir, The excretion of Silodosin can be decreased when combined with Ritonavir.]
[C07AB01, practolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Practolol is combined with Silodosin.]
[C02CA01, prazosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Prazosin is combined with Silodosin.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Silodosin is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Silodosin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Silodosin can be increased when combined with Primidone.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C01BC03, propafenone, The excretion of Silodosin can be decreased when combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Silodosin can be increased when it is combined with Fexofenadine.]
[N05AC01, periciazine, Periciazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N05CM06, propiomazine, Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Silodosin.]
[C07AA05, propranolol, The risk or severity of orthostatic hypotension and dizziness can be increased when Propranolol is combined with Silodosin.]
[B01AC09, epoprostenol, The risk or severity of orthostatic hypotension and dizziness can be increased when Epoprostenol is combined with Silodosin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Silodosin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[C01BA01, quinidine, The excretion of Silodosin can be decreased when combined with Quinidine.]
[P01BC01, quinine, The excretion of Silodosin can be decreased when combined with Quinine.]
[C02AA01, rescinnamine, The risk or severity of orthostatic hypotension and dizziness can be increased when Rescinnamine is combined with Silodosin.]
[C02AA02, reserpine, The excretion of Silodosin can be decreased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Silodosin can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Silodosin.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Silodosin.]
[C07AA07, sotalol, Sotalol may increase the orthostatic hypotensive activities of Silodosin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Silodosin.]
